Kiora Pharmaceuticals (KPRX) Q1 2025 earnings summary

Executive summary

• Kiora is advancing KIO-301 for vision restoration in degenerative retinal diseases and KIO-104 for retinal inflammation, with both entering Phase 2 trials in 2025.

• Entered a global licensing agreement (excluding Asia) with Théa Open Innovation for KIO-301, receiving a $16M upfront payment and potential milestones up to $285M.

• Reported preclinical data supporting KIO-104's potential in inflammatory and proliferative retinal diseases.

• Cash and short-term investments are expected to fund operations into late 2027, beyond anticipated data readouts for both trials.

Financial highlights

• Q1 2025 net loss was $2.2M, compared to net income of $13.4M in Q1 2024, reflecting the absence of a $16M upfront payment.

• No revenue recognized in Q1 2025; Q1 2024 included $16M from Théa.

• R&D expenses rose to $2.5M in Q1 2025 (before $1.3M reimbursement), up from $1.7M in Q1 2024.

• G&A expenses increased to $1.5M in Q1 2025 from $1.3M in Q1 2024.

• Ended Q1 2025 with $3.8M in cash, $20.3M in short-term investments, and $24.1M total liquidity.

Outlook and guidance

• Cash and investments are expected to fund operations into late 2027.

• Enrollment for both KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials is expected to begin in Q2 2025.

• Anticipates higher net R&D expenses in 2025 due to patient enrollment for KLARITY.

• Additional financing may be required for future development and commercialization.